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Abstract
Tissue  Engineering  concerns  the  three-dimensional  cell  growth so  that  bio-artificial  tissues  could  be
created and used for transplantation. Looking at the history of Tissue Engineering we could see that very
few of the promises have been implemented in clinics. The recently expressed concerns from the Tissue
Engineering research community for a re-direction of the research activities necessitate the proposition of
new methodologies. The methodology we propose here in general terms has to do with the simulation in
bioreactor  systems  of  liver  structures  as  are  described  in  liver  anatomy  so  that  the  hepatocyte
microenvironments that determine their function could be re-created in vitro. 
Much of the time for this project has been devoted in preliminary design of this approach, reviewing
information from literature for the phenomena involved in the establishment of liver tissue functions from
cooperative  cell  interactions  and  making  the  most  methodological  and  compatible  choices  of  the
bioreactor systems. 
The approach needs the use of hepatocyte aggregates as entities to load the bioreactor systems. A new
bioreactor,  the  microgravity  simulating rotation bioreactor,  has  been used  for  the preparation of  cell
aggregates. Two methods have been applied, the aggregation of cells alone and the aggregation with the
involvement of microcarriers (Cytodex 3) on which the cells attach. 
HepG2 cell  aggregates with microcarriers and spheroids were prepared, setting the conditions for the
production, protocols to monitor the cell culture, and their characterization.  Direct count with trypan blue
and qualitative image analyses were used to characterize the aggregates.  Preliminary toxicology assays
with acetaminophen (APAP) as toxicant in a range of 5 to 80 mM were carried out using standard culture
and the aggregates.  Total protein, DNA content and viability assayed with MTT were used to evaluate the
toxicity. As a consequence of the results obtained, improvements in the methodology are needed. New
experimental techniques, such as the assessment of cytochrome P450 isozyme activity will be used to
determine the feasibility of the 3 D model (in comparison with the standard 2D culture). 
In order to be able to study the heterogeneity within aggregate confocal microscopy is proposed as a valid
method to incorporate in the characterization of the aggregates as well as in the toxicological tests. 
Microcontact printing was used successfully to produce a patterned surface. This surface was tested for
BSA  protein  and  the  presence  of  the  pattern  confirmed  by  fluorescence  microscopy  and  AFM.
Immobilization of cell aggregates on protein-patterned surfaces will be attempt.
Once ready to move to the next stage, the work will consist in the production of primary rat hepatocytes
aggregates following the methods developed and it use in bioreactors with different configurations aiming
to gain further understanding of the role of cell heterogeneity in the cooperative behaviour of cells in
vitro.
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1. Introduction
Tissue engineering is a field of few decades history and involves several different areas such as cell and
molecular biology, materials science, reactor engineering, and clinical research [1]. As it was defined in a
workshop  of  the  National  Science  Foundation  of  USA in  1993,  it  involves  the  “the  application  of
principles and methods of engineering and life sciences toward fundamental understanding of structure-
function relationships in normal and pathological mammalian tissues and the development of biological
substitutes to restore, maintain or improve tissue function”. 
1.1 The significance of the three-dimensional cell growth
Tissue  Engineering  initiated  as  a  distinct  research  field  when  the  concept  of  cell  growth  in  three-
dimension (3D) was introduced. This was implemented by Bob Langer, a Chemical Engineer in MIT and
Joseph Vacanti,  a  Medical  Doctor  in  Harvard  in  1980  [2],  seeding cells  in porous biomaterials  and
suspending them in medium containing nutrients,  oxygen, and growth factors  in a  bioreactor  system.
These  scaffolds,  whose  pore  network  simulates  the  in  vivo vascular  network,  make  possible  the
maintenance of the cell viability with the adequate provision of nutrients and oxygen inside the cell mass.
The cells spread, move, divide and occupy the external surface of the material. 
The three-dimensional cell growth does not only resembles the geometry of real tissues, it is rather a basic
requirement for the cells to retain their differentiated phenotype through cell-to-cell interactions. It has
been proven that cells taken from tissues and placed in two-dimensions on a culture dish, gradually loose
the tissue functions that were performing, and soon die. In contrast, cells in aggregates are more functional
and  live  longer.  This  is  a  general  trend  observed  for  many  cell  types,  e.g.,  hepatocytes  [3],  or
chondrocytes [4].
1.2 The current situation in Tissue Engineering 
Why in vitro tissue formation cannot be easily optimized
The research efforts in Tissue Engineering have concentrated until now in the design of in vitro systems
(i.e. scaffolds, bioreactors, media and differentiation factors) improving cell level indices (e.g. longevity
of cell, viability and differentiation markers). Considerable progress was made at the technical level if we
take into account that few decades ago it was impossible to keep the cells taken from organisms viable in
vitro for the time needed for tissue development. Unfortunately however, none of these indices is directly
related with the tissue function, it is rather their combination that determines the tissue formation and
function. What is the appropriate combination of cell  characteristics, and how this combination arises
during the in vitro culture from an  optimal combination of the design parameters such as cell  types,
material scaffold properties, growth factors and bioreactor systems, has not been found yet making bio-
artificial tissues sub-optimal in their  functionality. The interrelation of  the design parameters  and the
unknown way they influence cellular functions make impossible a methodological approach as in other
Engineering fields (e.g., an increase in the porosity of the scaffold may increase the cell viability due to
better oxygenation, but may also prevent differentiated functions with the dilution of growth factors that
are secreted by the cells). Trial-and-error methods remain the only approach, having however a high cost
as  it  is  reflected  in  the high risk of  product  development of  the Tissue  Engineering companies.  Re-
engineering a candidate product to achieve better properties proved to be a very difficult problem [5].
Some of the recent failures  of the private sector  as  the  bankruptcy of  Advanced Tissue Science and
Organogenesis, were attributed to the lack of basic understanding [6].
Consequently until now, the successful developments of tissue engineering are just a few. The skin grafts,
which were one of the first therapies to be approved, are commercially available. Cartilage is also being
used and it is in clinical trial. Although researchers are currently pursuing tissue-engineered structures for
a host of tissues including bone, liver, artery, nerve, pancreas, skin, kidney, and bladder, we have to wait
several decades before bio-artificial tissues will be available for transplantations. 
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According to Langer and Vacanti pioneers of Tissue Engineering  "in the next three decades, medical
science will move beyond the practice of transplantation and into the era of fabrication”.
The improvements that have been made in the three-dimensional cell growth provide opportunities for
several other applications such in in vitro toxicity tests, in vitro tests for drugs, or in vitro basic research
studies of tissue physiology. Even though, bio-artificial tissues developed until now are far from the real
tissues in functionality, they are closer to real tissues than the cells grown on two-dimensional dishes, and
then represent a better model for study.
1.3 Bio-artificial liver devices 
Bio-artificial tissues although not optimal, are an option in the cases where no alternative method to cure a
life threatening disease is available. Over 30,000 patients die every year in US from acute liver failure [7].
Although  liver  transplantation  can  save  these  patients,  no  available  livers  can  be  found  in time.
Unfortunately 1000 patients (80% of those with acute liver failure), die every year in US while awaiting a
donor liver for transplantation [8]. A temporal support of the patient with a liver support device until a
liver is found for transplantation is  therefore considered the only alternative solution. In addition, the
acute liver failure is reversible in some cases if the liver functions are substituted temporally until the liver
of the patient recovers.
There are several designs of bio-artificial liver devices, which reflect the multiple criteria that must be
considered,  as  transport  of  nutrients  and  oxygen,  immunoisolation,  minimum amount  of  liver  cells
required to replace the liver cells, etc. [7], [9],  [10]).  The different designs include hollow fiber, flat
plate, perfused beads/scaffolds bioreactors, etc. These bioreactors have two compartments, one for the
hepatocytes and the other for the blood of the patient, e.g. hepatocytes are outside the hollow fibers
through which the blood of the patient is perfused, (Fig. 1). In most of the cases the hepatocytes are
forming cell aggregates, attached on scaffolds or encapsulated in polymers, so that their differentiated
functions could be kept for long time in vitro.
Figure  1: The HepatAssist bio-artificial liver device developed by Circe Biomedical of Lexinghton, Massachesetts
based on the work of Prof. Demetriou, (see text), and used in clinical trials in Spain, Reina Sofia Hospital, Cordoba
and Clinico de Barcelona. The blood of the patient is perfused through the fibers of a hollow fiber bioreactor and it
is cleaned by hepatocytes residing in the space between the fibers.
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Several companies are in clinical trials, some examples are the Vitagen, the Hepatix, the Circe Biomedical,
the Algenix, the Excorp Medical,  and the Charite Virchow Clinic-Berlin [7]. The first case of a patient
treated in Spain, at the Unidad de Cuidados Intensivos, Instituto de Enfermedades Digestivas, Servicio de
Hepatologia, Barcelona, was reported in 2001 [11].
Clinical  trials  until  now have  proven  the  safety of  various  bio-artificial  liver  devices.  However,  no
evidence of the efficacy in treating the acute liver failure could be found yet, even with the most widely
used bio-artificial liver device, HepatAssist, whose development has taken several years ([12], [13]). The
most probable reasons for this failure are the unknown etiology of the acute liver failure in most of the
cases, the variability of the symptoms caused by the disease, and the inability to design functional liver
tissue in the devices or to improve their functions when needed [14]. The use of sliced liver tissues, which
present the original liver structure, work better than any other hepatocyte three-dimensional arrangement
made in vitro [15]. However, sliced liver tissue cannot solve the problem due to the short life span of such
cultures cause by the inappropriate  cell nutrition, and the limiting number of hepatocytes, that cannot
multiply easily in the amount needed. 
Further  development  in  bio-artificial  liver  devices  remains  as  an  open  question.  None  of  the  design
parameters of these devices refers to liver tissue functions, so a methodological optimization could be tried.
All the design parameters influence the tissue functions but indirectly, in a combined and unknown way. The
uncertainty for the next step in Tissue Engineering has been recognized officially. “Further basic science
studies in tissue engineering systems” has been recommended at the Symposium of Reparative Medicine in
National  Institute  of  Health  (NIH)  of  US,  together  with  the  “development  of  a  vision  for  Tissue
Engineering”, and a  replacement  of  trial-and-error  methods with “rational  design  approaches”,  but  no
recommendation has been provided on how the above changes could be accomplished [16]. 
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2. Hypothesis 
 A new conceptual framework for the definition of objectives
Two conclusions can be drawn from the history of successes and failures in Tissue Engineering. First, the
three-dimensional cell growth is an almost absolute requirement for the retention of cell viability and
functionality. Therefore in order to have the experimental basis for any “basic science study” in Tissue
Engineering as  recommended by NIH,  a  well-controlled  method for  three-dimensional  cell  growth is
needed irrespectively of the type of studies that will follow. 
The other conclusion is that the three-dimensional cell growth in the bioreactor tried until now is not the
only  requirement  to  restore  tissue  functions  in  bio-artificial  tissues.  How  can  this  happen?  If  cell
functionality is maintained in three-dimensional cell growth why the bio-artificial tissue is not functional?
Is it a problem that could be solved optimizing the functionality of the cells with further trial-and-error?
Or is a problem with the “basic understanding” of how a bio-artificial tissue should be designed?
In view of the official recognition in the Symposium of NIH mentioned above for a new vision in Tissue
Engineering, it makes no sense to propose various combinations of bioreactors, scaffolds, cell types and
growth factors adding another unsuccessful combination from the numerous possible. It should be rather
proposed a new vision and check experimentally if it can be methodologically implemented.
We think that a  underestimated until  now in Tissue Engineering aspect of tissues,  that  of the spatio-
temporal  organization  of  the  cell  activities  to  tissue  functions,  deserves  further  consideration  as  a
candidate concept on which new research directions could be developed. A tissue is not a random three-
dimensional collection of cells according to anatomical and physiological data. The cells are organized in
space so that they can properly cooperate. It is the cell cooperation that integrates over the whole space of
the tissue that appears finally as tissue functions. 
The above is not a theoretical consideration, it is what tissue physiology have proved experimentally in
vivo and  in vitro for various tissues.  For example the regulation of the concentration of glucose in the
blood is not a hepatocyte function but a liver function, i.e., it cannot be performed by a single hepatocyte
or by a random three-dimensional arrangement of hepatocytes in scaffolds. This function appears only by
the cooperation of metabolically heterogeneous hepatocytes that have complementary metabolic functions,
one that secretes glucose and one that consumes glucose (see Annex 1 for more details). These two types
of hepatocytes activate their metabolic functions at different times according to the level of glucose in the
blood [17]. Similarly the control of the cartilage growth during its development cannot be achieved by a
single chondrocyte or by a random three-dimensional collection of chondrocytes in scaffolds. The control
function it is not a cell function but a tissue function build by the cooperation of different chondrocyte
types that exchange protein signals forming a negative feedback loop among chondrocytes in early and
late differentiation stages that keeps the differentiation rate inside some limits [18]. Another example is
the controlled release of insulin, which is a property of pancreatic islets and not a property of beta-cells
[19].
In  conclusion  two  basic  properties  build  the  real  tissues,  the  cell  heterogeneity  concerning  the  cell
functions and the cell  cooperativity concerning the complementarity of these functions.  As far as we
know, it has not been checked in bio-artificial tissues if such functional cell heterogeneity has appeared,
although numerous data exist in tissue physiology for the significance of its role. A reason for the focus of
until now Tissue Engineering studies on the cell instead of the tissue level, could be the choice of the cell
and the levels below the cell (i.e., genes, protein) as a reference system. But it seems that this has started
to change, and Biology moves now from the cell and gene level to the levels above. For example research
priorities in cancer have shifted from the genes to the interactions among cancer cells and other cells in
the tumor, treating the tumor as a pathological tissue, (among the new research priorities defined in 2003
by the Cancer Research Institute of US is the “characterization of the interaction among a tumor,  its
microenvironment and the entire body” and the “definition of the dynamic communication among cancer
cells and surrounding cells”). Therefore, this is a general re-direction in biomedical research and Tissue
Engineering cannot remain outside.
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Design of culture systems where hepatocytes exhibit functional heterogeneity
The implementation of the concepts mentioned above of cell heterogeneity and cooperatively, however is
not straightforward. A major difficulty addressing this problem experimentally arises from the complexity
in the establishment of cell functions, i.e., cell functions are determined by the cell microenvironment but
it  is the cells  by themselves that  determine this microenvironment. For example,  the hepatocytes that
either  release  or  consume  glucose,  they  do  so  according  to  the  oxygen  concentration  in  their
microenvironment [20], which however is determined besides the fluidics of the system by the hepatocytes
themselves that consume the oxygen with different and not yet determined way.
To face this difficulty we propose to transfer information from liver physiology and anatomy to gradually
more complicated bioreactor designs that resemble the liver structure. We will start with the preparation
of hepatocyte aggregates but we do not consider these aggregates as components of a bio-artificial liver as
it was until now. We consider them rather as components of another bioreactor that resembles the basic
structure in the liver, the liver sinusoid, (see Annex 1), where we will try to implement the hepatocyte
heterogeneity. We further consider the bioreactor-sinusoid as a component of another bioreactor system
composed of several sinusoids, where we will try to implement the hepatocyte cooperativity. In addition to
the  use  of  conventional  bioreactors  such  as  tubular  or  packed-bed,  for  the  establishment  of  tissue
functions, we will use micro-patterned surfaces or combination of surfaces where cells or cell aggregates
are placed accurately, to simulate in smaller scale the liver structures. 
The culture systems proposed here are not bio-artificial liver devices. They are rather experimental model-
systems from which new design criteria  referring  to  the  tissue  level  for  bio-artificial  liver  could  be
determined.  These  experimental  model-systems  that  are  at  the  moment  designed  using  qualitative
information when functional  could be used for the extraction of mathematical  formulas that  describe
quantitatively  the  way heterogeneous  hepatocytes  interact  cooperatively,  offering  quantitative  design
criteria. For a bio-artificial liver to be developed these criteria should be combined with several other that
are related with the characteristics of the acute liver failure, e.g., toxic compounds in the blood of patients,
number of hepatocytes needed for quick cleaning of the blood, etc., which is far from the present project.
In our case we start with cell  aggregates with a concrete plan for a  methodological upgrading of the
structural complexity of the in vitro system (based on liver physiology and anatomy), so that chances to
move from the heterogeneity to cooperativity will be increased. 
Basic unit: Cell aggregates
Cells self-organize in vitro to form multicellular structures under suitable conditions. There are several
methods to prepare cell aggregates. Roughly they can be divided in two groups [21]: i) stationary culture
using for example dishes not covered with collagen (for anchorage-dependent cells the biological dishes
are covered with collagen to facilitate the cell attachment) or dishes covered with agar, where the cells are
prevented to attach on the surface, and ii) non-stationary culture such as shaking or spinning culture using
spinner  flasks.  These methods are  widely used,  however,  they have the problem that  imposes severe
physical constraints, so that the cells should have a significant tendency to aggregate in order to attach one
to another and form aggregates. For example in the shaking cultures, the shaking needed to keep the cells
in suspension makes the cells  to move fast,  then they have no time to  develop their  connections.  In
addition the shear-stress is harmful to cell membranes. 
The first important step is the preparation of cell aggregates choosing a suitable bioreactor system that can
give control on the aggregate properties and optimizing the conditions for the formation of aggregates. 
The Engineers of NASA designed a bioreactor that simulates microgravity (Fig. 2) in order to have a
system on earth for comparison with their experiments in space, [22]. 
11
Hepatocyte aggregates 
Figure 2: The various types of rotation bioreactors. a. Batch type rotating vessel, (used in this studies), and rotating
wall vessel, (cylinder). The second is used for large cell-biomaterial constructs. b. Perfused type used for long-term
cultures.
The “simulated microgravity” environment of the rotating bioreactor combines several beneficial factors
for cell culture in tissue engineering. First, fluid flows in a laminar regime at most operating conditions,
avoids the large shear stresses associated with turbulent flow and allows introduction of controlled and
nearly homogenous shear fields. The suspended cells rotate as a solid body, maintaining their relative
positions for long periods, allowing them to touch one another and find the appropriate receptors for
connection on their surface, or to construct cell-bridges between cells growing on microcarriers beads.
The low-shear environment, in combination with randomized gravitational vectors, restricts the diffusion
of factors secreted by the cells and needed for cell growth, away from the cell microenvironment. 
It was proven that under the conditions provided in this bioreactor the cells aggregate easily forming the
so-called spheroids, without necrotic cores, which mean that transport of nutrients was adequate without
turbulent flow. While several studies have been performed after that time in Tissue Engineering using this
bioreactor, (reference above), very few studies refer to hepatocytes, with first one that of Khaoustov et al.,
[23]  where  it  was  found  superior  performance  in  comparison  with  other  systems in  respect  of  the
aggregate size and culture longevity.
Microcarriers
Cells grown on microcarriers in the rotation bioreactor will be used in this study in order to increase the
rate of cell growth and size of the aggregates. Microcarriers are beads of polymer, on the surface of which
cells can attach and grow. The first microcarriers from cross-linked dextran were developed in 1967 by
van Wezel for the culture of anchorage depended cells in suspension [24]. Microcarriers facilitate the
formation of large aggregates, that was shown for the first time in a study by Avgerinos [25]. Cells were
cultivated  in  conventional  microcarriers,  (Cytodex 2,  Pharmacia),  and  grew normally.  After  the cells
reached confluence, the cells began to migrate toward one end of the microcarriers and form clumps that
jointed the microcarriers, (Fig. 3). The growth rate of the cells is increased with microcarriers because
anchorage-dependent cells do not grow fast if not attached. The increase in the growth rate makes faster
the formation of large aggregates. 
Figure 3: Cells attached on microcarriers multiply and cover the surface in monolayers. Further cell growth results
in multiple layers at several points that act as bridges between cell-populated microcarriers. 
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 Objectives 
Objective 1 (short term)
a) Preparation of HepG2 aggregates in the microgravity-simulating bioreactor with single cells
and microcarriers
An immortalized cell line, HepG2 is used considering that at this stage the work is mostly related with
technical aspects of the culture systems.  This will facilitate the experiments since these cells are readily
available and grow indefinitely in culture.
b) Characterization of the aggregates
c) Test of micro-patterning method 
The purpose at this stage is to test the patterning of surfaces with a protein for future application. 
d) Preliminary toxicity test with hepatocyte aggregates 
In vitro hepatocyte systems are widely used in toxicity tests of drugs since the liver is the organ for the
detoxification of compounds entering the blood. Since two different types of cell aggregates are formed in
this project, an immediate use of them is toxicity tests. At this stage the purpose is the design of the
experimental  set-up  for  the  toxicity  tests,  which  includes  the  modification  of  the  analyses  usually
performed on the cells in the commonly used tests with hepatocytes on flat surfaces.
Objective 2 (Medium term)
a. Use of aggregates in toxicity tests and comparison with classical methods.
b. Preparation of hepatocyte aggregates from primary hepatocyte
Although HepG2 cell lines are used in bio-artificial liver because they retain some of the differentiated
properties of the in vivo hepatocytes, they are not suitable for studies related with the glucose metabolism.
Glucose metabolism is altered in the immortalized cells making them to consume much more glucose than
the in vivo cells, and it seems difficult to establish conditions were these cells could also release glucose,
as it is required to establish metabolic cooperativity in vitro. Therefore the use rat primary cells, i.e., cells
extracted from rat livers will be required. Immortalized cell lines may be adequate for toxicity tests, [26].
Objective 3 (Long term)
Use of aggregates of primary hepatocytes in organotypic culture systems, conventional bioreactors
and micro-patterned surfaces, specifically designed to resemble the liver structures
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3. Materials and Methods
3.1 Cells
Human Hepatoma cell line HepG2 was used [27]. HepG2 passage nº 8 of ACAC nº HB-8065 was kindly
proportioned by the Biochemistry department of Medical and Health Science School, Rovira i Rovira
University in Reus, Tarragona. The cells were frozen, suspended in cell freeze media, and stored in liquid
nitrogen tank until used.
3.2 Chemicals
The basal medium used is DMEM (GIBCO), which concisely consist of glucose, essential aminoacids,
vitamins and salts. It is complemented with 10% fetal bovine serum (FBS, GIBCO), which incorporate
growth factors, lipids, hormones and minerals; 1% non-essential amino-acids 100X (GIBCO) which are
glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid,L- proline and serine;  1% penicillin-
streptomycin 100X (GIBCO) and a  2,5% of 0,16 M solution of L-glutamine (SIGMA). 
Other  products  used  were  trypsin–EDTA  10X  (0.5%  Trypsin,  5.3  mM  EDTA•4Na,  GIBCO),
acetaminofen  (APAP,  from  SIGMA),  Hoechst  33344  (SIGMA),  3-[4,5-dimetiltiazol-2-il]2,5-difenil-
tetrazolium brimide (MTT, SIGMA), and dimetil sulfoxide (DMSO, SIGMA).
3.3 Culture conditions
The cell culture was carried out  in a  CO2 incubator at  37ºC,  5% of CO2 in air,  and in a  humidified
atmosphere. Refer to annex B for more detail of the protocols used.
3.4 Measurements
Quantification  of  the  amount  of  cellular  material  was  done  by  direct  count  in  hemacytometer  and
measuring protein and DNA content. The total amount of protein was assayed by Biuret method in a
Cobas Fara Mira analyzer. DNA was estimated measuring the fluorescence of Hoechst 33344 with an
excitation filter of 355 nm and an emission filter of 460 nm, in a Fluoroskan spectrofluorimeter. It is based
in  the  fact  that  Hoechst  dye  inserts  in  the  DNA  among  rich  regions  of  adenine-thymine,  giving
fluorescence that is proportional to the DNA content of the sample.
Glucose content was assayed using an enzymatic colorimetic test (GOD-PAP method from QCA S.A.
Amposta, Spain) measuring at 546 nm with a Perkin Elmer Lambda 2 UV/VIS spectrophotometer. 
The released of lactate deshydrogenase (LDH) was estimated using a kit based on SFBC technique from
QCA S.A., Spain, in a Cobas Fara Mira analyzer. Since the LDH is a cytosol enzyme, the increase of
LDH activity in the medium is an indicative of cell lysis.  
 The viability of the cells was assayed using MTT. This method is base in the color change that MTT
tetrazolim salt  undergoes  from yellow to  dark  insoluble  formazan  caused  by  the  activity  of  various
dehydrogenase enzymes in the cells. The tetrazolim ring is cleaved in active mitochondria, and so the
reaction occurs only in living cells. The viability is expressed as a % of the viability of the cells in the
control assay. 
Before imaging the cells, to have a better visualization of them, MTT was added to stain the cells. In
contrast to trypan blue dye exclusion, hepatocytes dyed by MTT are both viable and metabolically intact.
Dead cells do not stain whereas dying cells may stain feebly and contain a few dark particles. The images
were taken using a Reichert-Jung Polyvar microscope and a Nikon camera model.
3.5 Growth curve in 2D
Tissue culture plates were seeded with 2x105 cell/ml per plate and 3 ml of complete medium. The cell
growth was followed for 96 hours.  Each day 3 plates were used for sampling. Samples of the medium and
cells to assay the remaining glucose, LDH release and protein were taken. Each measurement was done in
triplicate. 
14
Hepatocyte aggregates 
3.6 Growth in 3D
Bioreactor
Disposable 10 ml bioreactors  (Synthecom, Inc. Houston, TX) were bought to Cellon S.A. (Luxemburg).
Before  use  they were  rinsed  with PBS and  allowed to  incubate  over  night.  After  a  final  rinse  with
complete  medium, they were ready to use. For  the cell culture the reactor  was place  inside the CO2
incubator at 37ºC and the rotation adjusted. The sampling and the media exchange were done through
ports that allow the extraction of medium maintaining aseptic conditions.
Microcarriers
Cytodex 3, collagen coated dextran beads of 175 μm diameter bought to Amersham Biosciences (Spain),
were  used  as  microcarriers.   They  were  prepared  and  sterilized  according  to  the  manufacturer’s
instructions. Briefly, 0,03 gram of dry microcarrier beads were incubated with 1,5-3 ml of PBS at room
temperature for at least 3 hours to allowed the beads to swell. After they were rinsed with PBS, replaced
with  new one,  and  sterilized  by  autoclaving  at  115ºC,  15  minutes,  15  psi.  Prior  to  use,  sterilized
microcarriers were allowed to settle, the supernatant was removed and microcarriers rinsed with warm
37ºC medium. Microcarriers were then ready to use for culturing. Cytodex that had been hydrated and
sterilized was store in sterile PBS at 4ºC until needed. 
Cells 
Cells in a 75cm2 flask in exponential growth were tryspinised and then used to form aggregates with or
without microcarriers. The initialization of the culture is explained in the results section. 
Toxicological tests
Toxicological tests were carried out with acetaminophen (APAP), a commonly use anti-inflammatory drug
that can produce hepatotoxicity both  in vivo and  in vitro.  The experimental design consisted in testing
different concentrations of toxins (from 0,5mM to 50 mM) and its control,  each of them in triplicate.
Different  concentration of  toxicant  is  added  to  the  culture medium of plate  with cells  in  exponential
growth phase (in 2D or 3D). In controls no additon of toxic was done. After 24 hours of the addition of
the APAP cell mass estimation and viability test  were carried out.
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4. Results
4.1 Standard 2-D culture of HepG2
The standard culture in two dimensions of the HepG2 cells was carried out in order to verify the correct
growth of the cells in the medium chosen. The medium chosen enabled the cells to grow. As it is shown in
figure 4 in the first 24 hours there was a lag phase where the cells recovered from the subculturing process
and adapted to the new conditions. Between 24 and 72 hours, there was a growth period shown by the
increase amount of biomass measured as total protein, with a decrease of glucose concentration. After 72
hours of culture, the growth rate of the culture decreased because of a combination of factors such as:
glucose and other nutrients were in low amount or exhausted, accumulation of toxic metabolic byproducts
such as lactate and ammonia and restriction of the available surface area.
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Figure 4: Growth curves of standard culture of HepG2
4.2 Bioreactor experiments
The experiments were performed in the rotation bioreactor. Each experiment lasted at least a couple of
weeks considering the time that the cells require to grow. Due to the availability of only one bioreactor
only one experiment could be performed each time. 
4.2.1 Culture in 3D: Cytodex
Culture on Cytodex 3 enables the cells: i) to attach on the surface of beads, in this case spheres covered
with denaturalized collagen, and ii) to grow the cells in the suspension culture mode, in the bioreactor
The settings of the culture had to be fixed, that means: initiation of the culture, speed of rotation and
medium exchange. 
First,  the initiation of  the culture was optimized aiming to obtain the coverage of the surface of the
Cytodex and  minimize the  number of  cells  in suspension not attached to  micro-carriers.  Taking into
account the recommendations of Cytodex manufacturers about the amount of microcarriers to be use and
size of inoculum, several experiences were carried out. An inoculum of 4x106  cells and 0,03 g Cytodex
were directly placed in the bioreactor. It was filled with complete medium and rotation adjusted to 8 rpm.
The attachment of the cells was monitored by observation of a sample under a phase contrast microscope.
Because even after 2 days of culture the number of cells attached to the microcarriers was very low, this
initiation method was not used. 
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In order to keep the cells in contact with the microcarriers for more time, the culture was done in two
steps. First cells were allowed the to attach to the microcarriers in a plate with sporadic agitation, and
second the cells and microcarriers were transferred to the bioreactor. Leaving the cells to attach over night
ended in a strong attachment of cells to the microcarriers and formation of bridges between microcarriers.
The clumps of cells-microcarriers were big and not stable enough for further manipulations, so that once
they were put in the reactor formed masses of very different size. Actually the big size is not a problem,
the problem is that the clumps became big under not controlled conditions. If this had taken place in a
bioreactor where the fluidics is different there would be no problem with the size.
In order to avoid this, a lower inoculum and a bigger plate were used. 4x105 cells were put in a small petri
dish and after 1 hour, the content was transferred to a D=10cm petri dish and left overnight. The day after,
there were cells adhered to the carriers but still most of them had no cells. The content was transferred to
the reactor at the slowest rotation rate,  8 rpm. After 72 hours of cell culture the number of cells on
microcarries was of only 4 cells/microcarrier.
A bigger innoculum and a shorter period for attachment were tested. The cells were allowed to attach to
the  microcarriers  for  2-4  hours  only with sporadic  agitation every 30  minutes  for  1-2  minutes.  The
microcarriers and cells were transferred to the bioreactor and filled it with medium. The rotation rate was
set to 8 rpm. After 48 hours not too many cells were on the microcarriers and even after 7 days cells did
not cover the microcarriers. 
Considering the above, it seemed that the cells needed more time to attached to the microcarriers, but they
should not be static in order to avoid the formation of clumps. Then in order to increase the probability of
attachment of the cells  to the microcarriers after the resting period, the cells  were transferred  to  the
bioreactor and only half the of the reactor was filled with media. After 24 hours 1 of 10 microcarriers did
not have cells, and the surface of the other microcarriers were covered in a 50-100% by cells. After 48
hours, the same was observed but more detached cells could be seen. As the cells grew and did not have
surface to attach, they formed clumps of cells that detached form the surface of the microcarriers. 
Then the initialization conditions were fixed. Considering that the number of cells that are attached to the
microcarriers increases with time, in order to maintain them suspended, the rate of rotation has to be
adjusted. This control was done daily, adjusting the rotation of the reactor, which varied from 8 to 20 rpm.
Because of the high concentration of cells in the reactor, the media had to be changed in order to restore
nutrients and to dilute toxic compounds that might be produced. Half the medium was substituted with
fresh one (glucose concentration 1 g/l) every day. As figure 5 shows, the cell content of the reactor went
form 106 up to 107 and declined after 120 hours of culture.
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Figure 5: HepG2 culture in RWV on Cytodex. Two different experiments A and B
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Half of the glucose was consumed in less than 30 hours so in order to permit the cell growth the media
was changed daily. The frequency increased to twice a day after 60 hours of culture in order to avoid
having concentration of glucose below 0,1 g/l, or not so often but using more concentrated glucose
medium.
During the cell culture a qualitative study was done to evaluate the time that takes to cover the surface of
the microcarriers, since after that point the growth rate may decrease. As it can be seen in figure 6 the
microcarriers were covered almost completely after 72 hours. In spite of that, no decrease of the growth
rate was observed between 72-120 hours of culture. 
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Figure 6: Coverage of the surface of the microcarriers with cells
4.2.2 Culture in 3D: spheroids
Other possibility of 3D cell culture is the formation of spheroids, which results form the self-aggregation
of the cells among themselves. The cells after trypsinization are placed in the reactor filled until half of the
volume. After 24 hours the reactor is completed with fresh media and the rotation speed adjust.  As it can
be seen in figure 7, the diameter of the spheroids increased during the culture, until no more than     80
μm.
Figure  7: Images of the spheroids obtained.  (A) 24-hour culture; (B) 72-hour culture; (C) 96-hour culture; (D)
Amplification of the image of one spheroid.
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During the time of the cultures, the cell number increased form 106 to 107 cells/ml. The glucose was
monitored and the media change so that the concentration of glucose was not below 0.1 g/l. In order to
avoid extremely low glucose concentration, a higher glucose concentrated media was used (4.5 g/l). An
example of the growth curves obtained is shown in figure 8.
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Figure 8: Growth curve of HepG2 spheroids
4.3 Toxicology tests
In order to compare the response of the cells in 3D with the standard culture in 2D, toxicology test were
carried out using standard 2 D culture and cell aggregates. 
Toxicology test in 2D
As it can be seen in figure 9, the three parameters reported for the toxicological assays are % of DNA and
MTT with respect to the control and glucose in the medium. The % of cells measured as DNA decreased
drastically with the concentrations of  APAP assayed.  At 20 mM there  is  a  reduction of  about 60%,
increasing up to 70% with higher APAP concentrations. The decreased in the viability measured as % of
MTT seems to be a bit higher, which is expected, since the cells might be affected remaining alive 
but less viable. 
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Figure 9: 2D toxicological experiment
The glucose remaining in the medium shows that the cells in the control consumed almost the 75% of the
glucose of the medium, in contrast to the 30% of the 20mM to 25% of the 80 mM. This is in accordance
with the fact that the amount of cells decreased with the amount of APAP added. The ratio of the glucose
consumption and amount of DNA was calculated,  to  check if  this relation could be  related with the
presence of the APAP; but no clear trend was found.
Even when not presented, LDH assays were carried out to estimate the amount of cell lysis. It seems that
APAP interfered with the LDH assays. The values of the LDH content of the medium at t=0 h decreased
just after the addition of APAP. That explained why the results of the assays at different concentrations of
APAP after 24 hours of culture, were unexpectedly lower than the control. 
4.4 Surface pattering
See annex C
4.5 Other experiments performed
Characterization of the formation of aggregates
During the cell aggregates formation, samples from cells and medium were analyzed. Protein and DNA
assays were proposed to follow the increase of biomass. Since they requires only a sample volume of 50
μl and 150 μl respectively, their measurements could be done in triplicate to have a better estimation of
the value. The results obtained were not reliable since the variation among the triplicates was very high.
The sample preparation probably was one of the factors involved. Possibly the process of breaking the
cells was not strong enough, as well as the breakage of the clumps that formed after defrosting the sample.
LDH measurement of the medium was assayed to evaluate the degree of cell lysis in the reactor. The data
obtained from these assays was difficult to interpret, since the overall value seemed to be very sensitive to
uncontrolled factors. The fact that the medium had to be changed frequently, introduced a dilution factor
that had to be considered.  But in spite of that, sometimes the LDH measured after the change of the
medium was higher than the one before and than the value before the following medium change. This
probably was indicates that during the medium change, the system was being affected. 
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Because of that, the medium was changed carefully and rapidly, in order to avoid a long disturbance of the
cell culture. In spite of that, the results did not improve. 
Toxicological experiments in 3D
After carrying out the toxicological experiments using the cell aggregates, no convincing results were
obtained. The range of concentration tested was form 5mM to 50mM. Total protein and amount of DNA
were assay to measured the amount of biomass and the total number of cells and MTT as a viability assay.
First, MTT assays did not give any acceptable results. Even though the value of absorbency decreased as
the amount of toxicant increased, as it was expected, the fact that this has to be related with the amount of
cell present in the assay, make this analysis inconclusive. Also some technical problems were present in
the separation of the supernatant from the cells before the addition of the DMSO, and then may have
affected the final result. On the other hand, the DNA and protein results were not consistent, probably
presented the same problem as in the characterization of the aggregates.
In view of the above, when working with the cell aggregates, the total lysis of the cell was not being
achieved. In order to improve the sample preparation, it is proposed to use a homogenizer buffer together
with a physical treatment such as sonication or passage throw a thin syringe. 
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5. Discussion
In the 3 D culture systems, the production of aggregates of cells  with and without microcarrier  was
achieved. At the beginning of the work, it was evident that the attachment to the microcarriers as well as
the self-aggregation of the cells is very sensitive to current state of the cells after the subculture procedure.
The cells have to be kindly treated during the trypsinitation, otherwise the aggregation is not attained in
the suspension culture. Besides, it seems that the alterations of the culture regime have an impact on the
state of the cells that cannot be avoided. 
 In  the  production  of  the  cell  aggregates,  once  the  initialization  conditions  were  established,  the
production of aggregates with Cytodex 3 and spheroids was done. In both cases, with an initial population
of 106 cell/ml in the reactor, the cells grew until 107 cell/ml was after 72-96 hours of culture. The method
used to follow the cell growth was direct counting of cells with trypan blue, since due to the complications
of the system other methods were not successful. The information given by this method, complemented
with image analysis that  gave data  of  sizes  and surface coverage,  it  is  not  enough.  Since  the three
dimensional characteristic of the aggregates are the base of our system, other methods of characterization
are required. The conventional methods employed results in an average response among the population of
cells, so they do not permit to observe heterogeneity among cells in accordance with its localization in the
aggregate.  
The confocal microscope is an established tool in many fields of biomedical for imaging of cells within
fluorescently-label tissues. The method of image formation in a confocal microscope is fundamentally
different from that in a conventional wide-field microscope in which the entire specimen is bathed in light,
and the image can be viewed directly by eye. In contrast, the illumination in a confocal microscope is
achieved by scanning one or more focused beams of light, usually from a laser, across the specimen. The
images produced by scanning the specimen in this way are called optical sections.  It is then a      non-
invasive  method,  which uses  light  rather  than  physical  means to  section  the  specimen,  enabling the
automated  collection  of  3D data  in  the  form of  Z-series  [28].  Using  this  technology is  possible  for
example to have images of the distribution of alive and death cells  in the cell  aggregates,  using two
different fluorescent dyes that stain differently alive and dead cells. This would enable us to check the
presence of necrotic center in the aggregates as well as the relation with the size of them.
 This technology could also be applied in the toxicological test, giving information about the response of
the cells to the toxic and also the spatial distribution of it in the aggregate. In this study, the number of
cells and viability of them were the only response to the toxic measured. Other assays more specific to the
response of the toxic are needed since comparison with standard culture is a goal. 
Because we are interested in being able to check heterogeneity within the aggregates, the endpoints that
we are interested in are those in which spatial distribution is involve.
 The toxic used, APAP, is a hepatotoxicant bioactivated by specific P450s, mainly CYP 2E1, 1A2, and
3A4. One effective method of assessing cytochrome P450 isozyme activity is by the detection of resorufin
formation from alkoxyresorufin substrates.  Resorufin is  a  highly fluorescent  compound that  is  easily
measured.  Alkoxyresorufin substrates have been used  to  probe  the level  of  activity,  inducibility,  and
substrate specificity of various P450 isozymes in rodent, and human hepatocytes as well as hepatic cell
lines. [29].  The use of confocal microscopy permits the assessment of local P450 isozyme activity in
three-dimensional tissue or tissue-like structure in situ by detection of local fluorescence intensity. 
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6. Conclusion
• A methodology for the formation of HepG2 cell aggregates with microcarriers and spheroids using a
microgravity simulating bioreactor was developed. This involved:
o Optimization of the initialization conditions of the culture
o Identification of important factors affecting the formation of aggregates
o Setting conditions of reactor operation: velocity of rotation and medium exchange
o To establish protocols to monitor the cell culture
• A basic characterization of the cell aggregates was obtained. In order to visualized heterogeneity
within the aggregates confocal microscopy will be used.
• Toxicology test has been carried out on cell aggregates. As a consequence of the results obtained,
improvements in the methodology are needed. New experimental techniques, such as the assessment
of cytochrome P450 isozyme activity will be used to determine the feasibility of the 3 D model (in
comparison with the standard 2D culture). 
• Microcontact printing was used successfully to produce a patterned surface. This surface was tested
for BSA protein and the presence of the pattern confirmed by fluorescence microscopy and AFM.
Immobilization of cell aggregates on protein-patterned surfaces will be attempt.
In the above conclusion is shown what remains to do in this first stage of the work proposed. Once ready
to move to the next stage, the work will consist in the production of primary rat hepatocytes aggregates
following the methods developed and it use in bioreactors with different configurations aiming to gain
further understanding of the role of cell heterogeneity in the cooperative behavior of cells in vitro.
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Annex A
Glucose metabolism in liver
In order to apply the new concept of designing, a liver tissue function had to be chosen. The glucose
metabolism  was  selected  because  considerable  information  exists  in  liver  physiology  and  liver
biochemistry for the role of various enzymes involved. In addition considerable information exist for the
substances in the hepatocyte microenvironments that induce the expression of these enzymes. No such
detailed information exists for other liver metabolic functions.  
According to the “metabolic zonation” theory, the enzymatic activities of metabolic functions in the liver,
(oxidative  and carbohydrate  metabolism, amino acid and ammonia metabolism, cholesterol  synthesis,
xenobiotic metabolism, protective metabolism and plasma protein formation), are unequally distributed
among the periportal,  and perivenous, zones of liver  lobules.  The periportal hepatocytes specialize in
glucose release and glycogen formation via gluconeogenesis and the perivenous hepatocytes specialize in
glucose uptake for glycogen synthesis and glycolysis, (Fig. A1 and A2) [17]
The distribution of the metabolic activities in the periportal and perivenous hepatocytes allows the liver
to operate as a “glucostat” regulating the blood glucose concentration at relatively constant levels, (80 to
120 mg/100ml). The perivenous hepatocyts removes glucose from the circulation during the absorptive
phase  after  a  carbohydrate-rich  meal,  and  the  periportal  hepatocytes  releases  glucose  during  the
postabsorptive phase when the glucose concentration in the blood is low in order to supply the central
nervous system and the erythrocytes, (Fig. A1). 
Figure 10: Liver lobule. The liver lobule is composed of sinusoids, narrow veins for the blood flow. At the walls of
the sinusoids are the hepatocytes. Periportal hepatocytes are situated close to the blood entrance and preferentially
release glucose, while perivenous hepatocytes at the blood exit consume glucose
The metabolic reactions of the glucose metabolish and the enzymes that participate are included in the
fig.  A2.  In few words the glucose that  is  taken up during the absorptive phase is  incorporated  into
glycogen and then when the glycogen stores are replenished it is degraded to lactate. Lactate then is
transported  by  the  circulation  to  the  periportal  cells  where  it  is  converted  via  gluconeogenesis  to
glycogen. Glycogen is degraded to glucose in the periportal cells during the post-absorptive phase. Then,
besides  the  heterogeneity  in  the  metabolic  functions  of  hepatocytes,  another  critical  factor  is  the
metabolic cooperativity through the transport of lactate. 
26
Glucose
Glucose
Blood flow
Perivenous
hepatocytesPeriportal 
hepatocytes
Hepatocyte aggregates 
Figure 11: Glucose homeostasis in the liver. Glc, glucose; Gg, glycogen; Lac, lactate; Pyr, pyruvate; G6P, glucose
6-phosphate; G6Pase, glucose 6-phosphatase; GK, glucokinase; PKL, pyruvate kinase type L; FBPase, fructose 1,6-
biphosphatase; PCK, phosphoenolpyruvate carboxykinase [30]
Most of the enzymes of carbohydrate metabolism have higher activity in the periportal or the perivenous
hepatocytes.  The  key  enzymes  of  gluconeogenesis,  glucose-6-phosphatase  (G6Pase),  fructose-1,6-
bisphosphatase (FBPase),  and phosphoenolpyruvate carboxykinase (PCK),  are periportal,  and the key
enzymes of glycolysis, glucokinase (GK), and pyruvate kinase isoenzymes L (PKL), are perivenous. The
unequal spatial distribution of enzyme activities is due to either regulation at pre-translational level (e.g.
phosphoenolpyruvate  carboxykinase)  or  regulation  at  translational  or  post-translational  level  (e.g.
glucokinase, pyruvate kinase L),[17]).
The zonal patterns of the gene expression related with the glucose metabolism have been categorized as
“gradient” type because all the hepatocytes are able to express these genes but the level of expression
depends on the position of  the cell along the sinusoid.  The  gradients  of  substances arising from the
exchange  of  metabolites  between  the  hepatocytes  with  the  flowing  blood  induce  differential  gene
expression [31]. The gradients related with the glucose metabolism are the gradients of oxygen and the
hormones glucagon and insulin. Most important is the gradient of oxygen which is the steepest falling by
50% from the periportal to the perivenous zone. 
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Anex B
Protocols
Cell defrost
Cells were kept in N2(l) until use. To start the culture, one ampoule was defrosted by addition of warm
DMEM (37ºC). DMEM was slowly added to the cryotube and was transferred to two 15 ml tube. Once
completely defrost, it was centrifuged at 1000 rpm for 3 minutes. The supernatant was discarded and more
DMEM was added to completely eliminate the DMSO. It was again centrifuge for 3 minutes at 1000 rpm
and the medium discarded. Finally cells were resuspended with complete medium and transferred a to
tissue culture flask for culturing.
Subculture
Cells in flasks were observed under a phase contrast microscope on alternating days to inspect the state of
the cells. After confluence is reached, which means that all the available growth area is utilized and the
cells make close contact with one another, cells will overgrow, which means that probably if subculture a
longer lag phase will be found. Then, subculture is done at 80% confluence.
Cells were twice rinsed with phosphate buffer solution (PBS) to remove the cell culture media from the
flask. The PBS was removed and trypsin  formed by a 1:10 dilution of 10X trypsin  in PBS, was added to
the flask which was incubated for 1 minutes at 37 °C. After that, trypsin was agitated by a pipette to
facilitate cell detachment from the plate. FBS was added to stop the action of trypsin The cell suspension
was removed from the flask and placed in a sterile 15 mL tube and centrifuged for 3 minutes at 1000 rpm.
The supernatant was removed and replaced with complete media, and the cells were resuspended. These
cells  could either be replated on tissue culture flasks to  expand the culture or  used for  the different
experiments. 
Sampling 2D culture
First a sample of the medium was directly taken from the plate. After 3 minute-centrifugation at 1000 rpm,
they were stored at –80ºC until assayed. The rest of the medium was discarded and the cells washed with
twice with PBS. The PBS was removed and trypsin formed by a 1:10 dilution of 10X trypsin  in PBS, was
added to the flask which was incubated for 1 minutes at 37 °C. After that, trypsin was agitated by a pipette
to  facilitate  cell  detachment  from the  plate.  FBS was added  to  stop  the  action  of  trypsin.  The  cell
suspension was removed from the plate and placed in an eppendorf tube and centrifuged for 3 minutes at
1000 rpm. The supernatant was removed and cells resuspended in 1 ml of PBS. In order to eliminate any
rest of FBS, it was again centrifuged idem before. Cells resuspended in 1 ml of PBS were kept at –80ºC
until assayed.
3-D cell culture
Replacing culture media
When Cytodex was used the content of the reactor was allowed to sediment for 15 minutes and then the
media was changes. Because the spheroids did not sediment easily, media was extracted with a syringe
through one of the port through a 0,5 mm filter in order to avoid the lost of cells. Afterwards pre-warmed
complete medium was added, and absence of bubbles checked.
Sampling 3D culture
1 ml sample of the content of the reactor was taken while it was rotating with a syringe, and the same
volume of  medium was added in order  to  avoid bubbles  inside  the reactor.  Cells  and  medium were
separated for later assessment. The medium was store at –80ºC until assayed, and the cell sample taken as
explained in cell harvesting section.
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Cell harvesting
The spheroids as well as the Cytodex 3 covered with cells could be visualized directly by phase contrast
microscopy. In order to be able obtain a homogenous cell sample, trypsinition of the cells was done in
order to detach cells from the microcarrier and/or from other cells. 
For cells on Cytodex 3, the microcarriers were allowed to settle, culture medium was removed, and the
microcarriers were washed for 5 minutes in PBS containing 0,02% (w/v) EDTA, pH 7,6. The EDTA-PBS
is removed an replaced by trypsin-EDTA and incubated with occasional agitation. After 15 min. the action
of the trypsin is stopped by addition of FBS. The sample is centrifuge again and suspended in 1 ml of
PBS.
In the case of the spheroids,  they were centrifuged for 5 minutes at  1000 rpm. Culture medium was
removed and washed for  5  minutes in PBS containing 0,02% (w/v) EDTA, pH 7,6. After 3  minutes
centiguation at 1000 rpm, the EDTA-PBS was removed an replaced by trypsin-EDTA and incubated for
15 minutes with occasional agitation. The action of the trypsin was stopped by addition of FBS. The
sample is centrifuge and suspended in 1 ml of PBS.
Measurements
Direct cell count with trypan blue
Typan blue is a dye that is taken up by dead cells, but excluded by living cells. 500 μL of a very well
mixed cell suspension obtained according cell harvesting protocol, was place in an eppendorf and added
equal volume of the diluted dye. Cell count in a hemacytometer was done.
DNA with Hoechst 
100 μL of the cell sample was placed in a 96 well plate by triplicate and 50 μl of Hoechst solution is
added in order to obtain a final concentration of 10 μg/ml. After 1-hour incubation at 37ºC, fluorescence
is measured.
Viability with MTT
After cell harvesting, the cells were resuspended in complete medium, and 100 μL cell sample was placed
in a eppendorf tube by triplicate. 10 μL of 5mg/ml MTT solution is added to each tube. After 3 hours of
incubation at 37ºC, and 3 minutes centrifugation at 1000 rpm, the medium is discarded and 100 μL of
DMSO  is  added.  To  measure  the  absorbance,  the  sample  was  transferred  to  a  96  well  plate  and
absorbance read at 550/620 nm with BioWhittaker Kinetic QCL plate-spectrophometer.
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Annex C
Surface pattering using micro-contact printing
Chemically microstructured surfaces have gained increasing attention in the cell biological/biomaterial
community in the past  few years.  There is  a  broad field of practical  applications of micro-structured
substrates, ranging from tissue engineering through cell array-based biosensors to artificially designed
neuronal  networks.  Among  the  numerous  methods  to  pattern  biomolecules  on  a  solid  surface,
microcontact  printing  (μCP)  is  becoming  increasingly  popular.  There  are  several  reasons  for  this
popularity, μCP is a simple and cost-effective method, does neither require clean room instrumentation
nor absolutely flat surfaces, plus it offers a way to create complex patterns (yet with some geometrical
constraints) on surfaces.  Besides, in contrast to patterning methods that are based on photolithography,
μCP does not subject any of the patterning materials to harsh chemical or physical treatments that most
biological  molecules.  All  printing occurs  in  ambient  conditions,  and  all  post-printing steps  occur  in
aqueous solutions that do not denature proteins. In addition, the use of a soft deformable stamp as the
patterning element allows patterining over large areas [32].  
The objective of this work was to learn the microcontact technique, apply it to obtain a protein-patterned
surface of bovine serum albumin (BSA) and use fluorescence microscopy and atomic force microscopy
(AFM) to confirm the presence of the pattern.
Materials and methods
The silicon masters used for producing the microcontact-printing were provided by GemSin, Germany.
Poly(sodium-4-styrensulfonate)  (PSS,  Mw=70000  g/mol),  poly(allyamine-hidrochloride)  (PAH,
Mw=700000 g/mol), poly(ethyleneimine) (PEI, Mw= 25000 g/mol) were purchased form Aldrich. Poli-L-
lysine  grafted  polyethilen  glicol  (PLL-g-PEG/PEGbio  (20)-[3.5]-(2,3,4)  (50%  bio)  was  provided  by
Surface Solutions. It is a graft copolymer with a PLL backbone of molecular weight of 20 kDa, a grafting
ratio of lysine-mer/PEG side chain of 3.5   with molecular weight of 2 kDa. Rhodamine-B-isothiocyanete
label PAH (RBITC-PAH) was prepared as described by Richter et al and Ibarz et al. The FITC-PAH was
purchased  from Capsulution  NanoScience  AG(Berlin,  Germany).  BSA form Sigma was labeled  with
TRICT using standard methods. 
PDMS base silicon elastomer Sylgard 184 and the curing agent (Dow Corning Midland, MI) were mixed
in a 10:1 ratio, and degassed in a vacuum. The masters were covered with the pre-polymer, degassed
again, and cured for 12h at 60ºC. The stamps were cut out and hydrophilized in an air-plasma cleaner
(Harrick PDC-32G-2, pressure: 5 mbar, 1 min).  Before the stamping was carried out, a 1mg/ml solution
of  the  polyelectrolyte to stamp (PAH  in  500 mM NaCl or PLL-g-PEG) was spread on the stamp. After
15 minutes, the stamps were briefly rinsed with water an excess solution was removed in a steam of
nitrogen. The inked stamps were brought into contact with clean and dried coverslips with or without
coating for 20 minutes and then removed. The structured surfaces were carefully rinsed with water. The
adsorption of the BSA was done by covering the area of interest with a drop of the solution and left for 5
minutes and afterwards carefully cleaned with water. The cleaning of the coverslips prior coating with
polyelectrolytes was based in the RCA method.  Briefly,  the coverslips were put in 98% ethanol and
sonicated for 15 minutes. After rinsing with water, they are immersed in a solution of H20:NH4OH:H2O2
5:1:1 at 70ºC for 15 minutes. After intensive rinsing with water, the coverslips are ready to use.  In the
case of  PLL-g-PEG stamping after 15 minutes sonication in ethanol 98% were followed  with 2 minutes
of plasma cleaner.
Fluorescence  microscopy  imaging  was  carried  out  on  Zeiss  Axiovert  200  (Zeiss,  Germany)  with  a
Axiovert  LDA-Plan  10X,  light  source  was  Hg  vapor  lamp.  A  Zeiss  Axiocam  HR  high-resolution
monochromatic  camera  was used.  Atomic force  microscopy (AFM) measurements  were done  with a
Nanoscope IIIa AFM in tapping mode.
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Results and discussion
1) Polyelectrolyte patterning
The first  μCP attempts were done using fluorescently label PAH in order to be able to check easily the stamped
pattern.  The RBITC-PAH pattering on glass coated with one layer of PEI and PSS was obtained as it is shown in
fig.C1.
Figure 12: PAH patterns on PEI-PSS coating on glass coverslips. (A) PAH is the complementary area of D= 10μm
circles; (B) strips of  aprox. 5μm.
Then it was of interest to check the possibility of selectively covering the surface of a patterned substrate with a
polyelectrolyte.  The selective  adsorption  of  FITC- PAH was tested.  As it  can  be  seen in  the  fig.  2,  the  FITC-
PAH/RBITC-PAH  pattern  is  observed  clearly.  Applying  the  same  technique,  PLL-g-PEG  was  stamped  and
afterwards RBITC-PAH was added. Figure C2 shows that even though it is not so clean, the pattern polyelectrolyte
pattern was obtained.
Figure 13: Pattern of FITC-PAH and RBITC-PAH. (A) Image of the FITC-PAH pattern; (B) Image of the RBITC-
PAH pattern; (C) PLL-g-PEG pattern and RBITC-PAH.
2) BSA patterning
In order to obtain the resistant protein pattern PLL-g-PEG was used. After stamping the glass slide, TRICT-BSA was
put on the surface of the slide. Fig. C 3 and C4 proves that the protein resistant surface of the polyelectrolyte prevents
the BSA to attach in those areas where PLL-g-PEG was stamped. 
Figure 14:TRICT-BSA on glass with protein resistant pattern of  PLL-g-PEG. (A) strips 10 μm width, (B) squares .
AFM measurements of the high differences of the surface were done by AFM before and after the addition
of the BSA. Figure C4 shows one experiment of BSA adsorption.
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Figure C4: PLL-g-PEG pattern on glass surface before the protein adsorption. (A) High differences of the section
shown in figure B before any mathematical treatment. (B) Image of the pattern after performing a second order
flattening.  (C)  Result  of  the  bearing  analysis  of  data  of  figure  B.  (D)  Fluorescence  microscope  image  of  the
patterning after the adsorption of BSA.  (E) AFM image of the patterning after the adsorption of BSA.  (F) Section
average of the surface obtained after the adsorption of the BSA.
 As it can be seen in figures C4, it was possible to confirm the presence of the PLL-g-PEG. The heights
differences measured were in two sets of experiments of 2,3±0,3 nm (n=3) and 9,3±2,5 nm (n=13). As it
can be seen it was no possible to obtain a reproducible height difference in the stamping.
After the adsorption of the BSA, the differences in height were reduced, in the first case to 1,6±0,4 nm
and in the second case 1,5±1,0 nm. 
In figure C3, it is clearly seen that the broader strips that in figure C4 A and C4B correspond to the bare
glass are covered with BSA as shows figure C4D, showing that the BSA has selectively adsorbed in that
area.
In both cases the amount of protein adsorbed was such that after the adsorption, the surface obtain had
almost no difference in height, then the amount of protein adsorbed seems to have been controlled by the
height of the PLL-g-PEG pattern, since in both cases the time and concentration of the protein was the
same. 
Conclusion
A BSA patterned surface was attained by μCP of PLL-g-PEG and it presence checked with AFM. Further
work will involve choosing a protein of interest, pattern it using this technique, and afterward test if cell
aggregates can be selectively immobilized on the surface.
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